Decoy Therapeutics (NASDAQ:DCOY) Releases Quarterly Earnings Results

Decoy Therapeutics (NASDAQ:DCOY) released its quarterly earnings results on Tuesday. The company reported $43.10 earnings per share for the quarter, FiscalAI reports.

Decoy Therapeutics Trading Down 3.4%

Shares of NASDAQ DCOY traded down $0.23 during midday trading on Tuesday, reaching $6.53. The company’s stock had a trading volume of 38,425 shares, compared to its average volume of 32,354. Decoy Therapeutics has a fifty-two week low of $5.94 and a fifty-two week high of $415.80. The stock’s 50 day moving average price is $8.29. The firm has a market cap of $3.46 million, a P/E ratio of -0.02 and a beta of 0.30.

Analysts Set New Price Targets

Several equities research analysts have issued reports on DCOY shares. Wall Street Zen upgraded Decoy Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Weiss Ratings began coverage on shares of Decoy Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Finally, LADENBURG THALM/SH SH began coverage on shares of Decoy Therapeutics in a report on Friday, January 23rd. They set a “buy” rating and a $30.00 target price on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Decoy Therapeutics has an average rating of “Hold” and an average target price of $30.00.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.